Omaran Abdeen, MD
Nephrology · Mission Hills, CANPI 1700878410
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Amgen at 36.0% of the total.
Across 114 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$842
- AstraZeneca$212
- Novo Nordisk$197
- Otsuka America Pharmaceutical, Inc.$150
- Mallinckrodt Hospital Products Inc.$107
- Akebia Therapeutics Inc$106
- plus $722 from 13 others
Across 496 payments — averaging $1179.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$543K
- OPKO Pharmaceuticals, LLC$27K
- Travere Therapeutics, Inc.$9K
- CSL Behring$6K
What the payments were for
- Food & beverage$2,336100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 49 | $842 |
| AstraZeneca | 12 | $212 |
| Novo Nordisk | 8 | $197 |
| Otsuka America Pharmaceutical, Inc. | 6 | $150 |
| Mallinckrodt Hospital Products Inc. | 4 | $107 |
| Akebia Therapeutics Inc | 5 | $106 |
| Fresenius USA Marketing, Inc. | 5 | $105 |
| GSK | 3 | $101 |
| Boehringer Ingelheim | 5 | $100 |
| Vifor Pharma, Inc. | 5 | $98 |
| Amarin Pharma, Inc. | 1 | $75 |
| Bayer | 3 | $73 |
| Boston Scientific | 1 | $43 |
| Johnson & Johnson | 2 | $39 |
| Novartis | 1 | $25 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| OPKO Pharmaceuticals, LLC | 1 | $16 |
| Sanofi | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
How this compares
$2,336 in reported general payments places this provider in the 65th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 43 | $138,245 |
| EliquisApixaban | 69 | $64,985 |
| FarxigaDapagliflozin Propanediol | 50 | $40,899 |
| AuryxiaFerric Citrate | 18 | $35,088 |
| XphozahTenapanor Hcl | 11 | $31,706 |
| VeltassaPatiromer Calcium Sorbitex | 31 | $30,911 |
| JanuviaSitagliptin Phosphate | 41 | $30,304 |
| OzempicSemaglutide | 32 | $29,542 |
| TradjentaLinagliptin | 30 | $25,715 |
| Sevelamer Carbonate | 89 | $22,211 |
| LokelmaSodium Zirconium Cyclosilicate | 40 | $21,171 |
| ProcritEpoetin Alfa | 14 | $14,805 |
| MounjaroTirzepatide | 14 | $14,538 |
| LinzessLinaclotide | 14 | $13,277 |
| EntrestoSacubitril/Valsartan | 11 | $13,111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $105 | $138,24543 claims |
| AstraZenecaFarxiga, Lokelma | $212 | $62,07090 claims |
| Boehringer IngelheimTradjenta, Jardiance | $100 | $35,81646 claims |
| Akebia Therapeutics IncAuryxia | $106 | $35,08818 claims |
| Novo NordiskOzempic | $197 | $29,54232 claims |
| Johnson & JohnsonProcrit | $39 | $14,80514 claims |
| NovartisEntresto | $25 | $13,11111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,341 nephrology providers in California.
Other nephrology in Mission Hills
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
- Suphamai BunnapradistLos Angeles$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.